NASDAQ:FENC Fennec Pharmaceuticals (FENC) Stock Price, News & Analysis $6.04 +0.38 (+6.71%) (As of 11/26/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Fennec Pharmaceuticals Stock (NASDAQ:FENC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Fennec Pharmaceuticals alerts:Sign Up Key Stats Today's Range$5.47▼$6.2750-Day Range$3.99▼$5.6652-Week Range$3.96▼$11.92Volume280,159 shsAverage Volume116,746 shsMarket Capitalization$165.67 millionP/E RatioN/ADividend YieldN/APrice Target$13.67Consensus RatingBuy Company OverviewFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.Read More… I've got news for you… (Ad)Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the weekwatch this FREE briefing with me and expert trader Graham Lindman Fennec Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks51st Percentile Overall ScoreFENC MarketRank™: Fennec Pharmaceuticals scored higher than 51% of companies evaluated by MarketBeat, and ranked 669th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingFennec Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageFennec Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Fennec Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings Growth-37.50% Earnings GrowthEarnings for Fennec Pharmaceuticals are expected to decrease by -37.50% in the coming year, from $0.08 to $0.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Fennec Pharmaceuticals is -60.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Fennec Pharmaceuticals is -60.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Fennec Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.76% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 3.26%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFennec Pharmaceuticals does not currently pay a dividend.Dividend GrowthFennec Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.76% of the float of Fennec Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverFennec Pharmaceuticals has a short interest ratio ("days to cover") of 19.5, which indicates bearish sentiment.Change versus previous monthShort interest in Fennec Pharmaceuticals has recently decreased by 3.26%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.85 News SentimentFennec Pharmaceuticals has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Fennec Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for FENC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Fennec Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Fennec Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,856.00 in company stock.Percentage Held by Insiders10.98% of the stock of Fennec Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions55.51% of the stock of Fennec Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Fennec Pharmaceuticals' insider trading history. Receive FENC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Fennec Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address FENC Stock News HeadlinesInsider Selling: Fennec Pharmaceuticals Inc (NASDAQ:FENC) Director Sells 2,431 Shares of StockNovember 5, 2024 | insidertrades.comFennec Pharmaceuticals (NASDAQ:FENC) Stock Rating Upgraded by StephensNovember 22, 2024 | americanbankingnews.com2025: Digital Asset Insights You Need to KnowCryptocurrencies are taking off again, and those in-the-know are positioning themselves to ride this wave in 2025. The question is—will you be one of them? With explosive growth on the horizon, there’s never been a better time to understand the potential gains in crypto. Our guide, Navigating the Future: Cryptos to Watch in 2025, reveals the cryptos leading this surge and the strategies to maximize your profit potential.November 27, 2024 | Darwin (Ad)Fennec initiated with an Overweight at StephensNovember 18, 2024 | markets.businessinsider.comFennec Pharmaceuticals to Participate in Upcoming Investor ConferenceNovember 13, 2024 | globenewswire.comFennec Pharmaceuticals Inc. (NASDAQ:FENC) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comFennec Pharmaceuticals Inc. (FENC) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comFennec Pharmaceuticals Inc (FENC) Q3 2024 Earnings Call Highlights: Strong Sales Growth and ...November 9, 2024 | finance.yahoo.comSee More Headlines FENC Stock Analysis - Frequently Asked Questions How have FENC shares performed this year? Fennec Pharmaceuticals' stock was trading at $11.22 at the beginning of the year. Since then, FENC stock has decreased by 46.2% and is now trading at $6.04. View the best growth stocks for 2024 here. How were Fennec Pharmaceuticals' earnings last quarter? Fennec Pharmaceuticals Inc (NASDAQ:FENC) posted its earnings results on Tuesday, August, 13th. The company reported ($0.20) EPS for the quarter, missing analysts' consensus estimates of $0.06 by $0.26. The business earned $7.26 million during the quarter, compared to analyst estimates of $13.67 million. Fennec Pharmaceuticals had a negative trailing twelve-month return on equity of 53.38% and a negative net margin of 2.30%. Who are Fennec Pharmaceuticals' major shareholders? Fennec Pharmaceuticals' top institutional investors include State Street Corp (1.20%), Advantage Alpha Capital Partners LP (0.19%), BNP Paribas Financial Markets (0.15%) and Barclays PLC (0.11%). Insiders that own company stock include Robert Andrade, Rosty Raykov, Chris A Rallis and Adrian Haigh. View institutional ownership trends. How do I buy shares of Fennec Pharmaceuticals? Shares of FENC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Fennec Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Fennec Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings8/13/2024Today11/26/2024Fiscal Year End12/31/2024Next Earnings (Estimated)3/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:FENC CUSIPN/A CIK1211583 Webwww.fennecpharma.com Phone919-636-4530Fax919-890-0490EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$13.67 High Stock Price Target$15.00 Low Stock Price Target$13.00 Potential Upside/Downside+126.3%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.10) Trailing P/E RatioN/A Forward P/E Ratio75.50 P/E GrowthN/ANet Income$-16,050,000.00 Net Margins-2.30% Pretax Margin-2.31% Return on Equity-53.38% Return on Assets-2.08% Debt Debt-to-Equity Ratio9.86 Current Ratio7.80 Quick Ratio7.64 Sales & Book Value Annual Sales$49.35 million Price / Sales3.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.43) per share Price / Book-14.05Miscellaneous Outstanding Shares27,428,000Free Float24,416,000Market Cap$165.67 million OptionableOptionable Beta0.27 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report This page (NASDAQ:FENC) was last updated on 11/27/2024 by MarketBeat.com Staff From Our Partners⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | SponsoredBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fennec Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fennec Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.